Details of Disease

General Information of Disease (ID: DISDSMNI)

• Disease Name: Back pain
• Disease Class: ME84: Spinal pain
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISDSMNI: Back pain
• ICD Code:
  ICD-11: ICD-11: ME84.Z
  Expand ICD-11: 'ME84.Z
  Expand ICD-9: 724.5,338,780
• Disease Identifiers:
  MESH ID: D001416
  MedGen ID: 2530
  HPO ID: HP:0003418
  SNOMED CT ID: 161891005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 11 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acetaminophen	DMUIE76	Approved	Small molecular drug	[1]
Aspirin	DM672AH	Approved	Small molecular drug	[2]
Caffeine	DMKBJWP	Approved	Small molecular drug	[3]
Capsaicin	DMGMF6V	Approved	Small molecular drug	[4]
Carisoprodol	DMWR1JC	Approved	Small molecular drug	[5]
Hydromorphone	DMHP21E	Approved	Small molecular drug	[6]
Menthol	DMG2KW7	Approved	Small molecular drug	[7]
Oxycodone	DMXLKHV	Approved	Small molecular drug	[8]
Pelubiprofen	DM8DQV9	Approved	Small molecular drug	[9]
Salicyclic acid	DM2F8XZ	Approved	Small molecular drug	[10]
Salicylamide	DMQXO1I	Approved	Small molecular drug	[11]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Chondrocyte tissue grafts	DMER49J	Phase 3	NA	[12]
Fulranumab	DMK38MV	Phase 3	Monoclonal antibody	[13]
ZX002	DMGYM2A	Phase 3	NA	[14]
Axomadol	DM0W5OQ	Phase 2	Small molecular drug	[15]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KUR-521	DMOK69X	Investigative	NA	[16]
methyl salicylate	DMKCG8H	Investigative	Small molecular drug	[7]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Acetaminophen FDA Label
• [2] Aspirin FDA Label
• [3] Caffeine FDA Label
• [4] Capsaicin FDA Label
• [5] Carisoprodol FDA Label
• [6] Hydromorphone FDA Label
• [7] methyl salicylate FDA Label
• [8] ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [11] Augmentation of musculoskeletal soft tissue morphology within low back pain patients may suggest the presence of physiological stress shielding: An in vivo study. J Biomech. 2024 Jan;162:111894.
• [12] Clinical pipeline report, company report or official report of ISTO Technologies.
• [13] ClinicalTrials.gov (NCT02336685) Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001. U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of Zogenix.
• [15] ClinicalTrials.gov (NCT01043263) Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain. U.S. National Institutes of Health.
• [16] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.